New Rapid COVID-19 Point of Care Test
Summary
Statement from Paul Danner, Chief Executive Officer - “We believe our suite of COVID-19 test products will provide a significant positive impact on the global effort to bring the pandemic under control. The other two devices use Pepex novel sensor technology to detect antibodies in interstitial fluid for presence, and the other to quantify titers, rapidly and accurately.All four test devices are self-contained and do not require additional diagnostic equipment or laboratory assistance.Statement from Paul Danner, Chief Executive Officer - “We believe our suite of COVID-19 test products will provide a significant positive impact on the global effort to bring the pandemic under control. Insight Innovation Center will provide Pepex with end-to-end development services from early to late-stage with design research, user experience, engineering, and human factors requirements. The Company has an extensive portfolio of over 300 global patents that protect proprietary manufacturing processes and unique biosensor designs for a broad base of applications including COVID-19, Sepsis, HIV, Ebola, Hepatitis, Lactate, Blood Sugar and other life-altering biomarkers. Pepex Biomedical’s mission is to become the leading technology source, prime supplier, and marketer of enzymatic and immunological biosensors for consumer medical devices and hospital diagnostic use.For more information, please contact Paul Danner, Chief Executive Officer, at paul.danner@pepex.com or +1.401.588.0110.
Classifications
AskAI Classifications
LabelsLinked Companies
